GlassScriptPhysician profile
Vincent V Miller
NPI 1457335002
$1,274.13
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,248 · 2020: $12.82 · 2021: $13.09.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $249.56 | 2019 | |
| Astellas Pharma US INC | $207.40 | 2019 | |
| Novo Nordisk INC | $178.88 | 2019 | |
| Amgen INC. | $161.94 | 2019 | |
| Glaxosmithkline, LLC. | $147.43 | 2019 | |
| Pfizer INC. | $131.02 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.03 | 2019 | |
| Ironwood Pharmaceuticals, INC | $27.51 | 2019 | |
| Sanofi-Aventis U.S. LLC | $26.42 | 2019 | |
| Mylan Specialty L.P. | $25.18 | 2019 | |
| Melinta Therapeutics, LLC | $14.89 | 2019 | |
| Shire North American Group INC | $13.86 | 2019 | |
| Abbvie INC. | $13.09 | 2021 | |
| Lilly USA, LLC | $11.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.09 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.